Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects

ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends

Excerpt from the Press Release:

DOYLESTOWN, Pa.–(BUSINESS WIRE)–​Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85^th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses.

ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation.

“Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies,” said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma.

Click the button below to read the entire Press Release:

Continue Reading The Press Release